On October 24, 2016, the US Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) announced the full implementation and indefinite extension of the Program for ...
Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly less expensive than branded on-patent medicines. Off-patent therapies — generics ...
Computer science is approaching a crisis that some CS experts say could fuel a renaissance of ideas. Very soon, mainstream computers will need an easy-to-use parallel programming model to tap into ...
A review of the last five years of the Parallel Scientific Advice (PSA) program between the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) shows that the agencies ...
The U.S. Food and Drug Administration and CMS announced an extension on their joint Parallel Review pilot program, according to a Regulatory Focus report. Launched in October 2011, the Parallel Review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results